These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 4832718)

  • 1. Clearance of antipyrine-dependence of quantitative liver function.
    Andreasen PB; Ranek L; Statland BE; Tygstrup N
    Eur J Clin Invest; 1974 Apr; 4(2):129-34. PubMed ID: 4832718
    [No Abstract]   [Full Text] [Related]  

  • 2. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
    Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
    Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impairment of drug elimination in patients with liver disease.
    Narang AP; Datta DV; Mathur VS
    Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of serum antipyrine half-lives in patients with liver disease.
    Branch RA; Herbert CM; Read AE
    Gut; 1973 Jul; 14(7):569-73. PubMed ID: 4729926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenazone metabolism in patients with liver disease.
    Andreasen PB; Greisen G
    Eur J Clin Invest; 1976 Jan; 6(1):21-6. PubMed ID: 1253807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination.
    Hepner GW; Vesell ES; Lipton A; Harvey HA; Wilkinson GR; Schenker S
    J Lab Clin Med; 1977 Sep; 90(3):440-56. PubMed ID: 894100
    [No Abstract]   [Full Text] [Related]  

  • 10. [Influence of rifampicin on the metabolic clearance of galactose and antipyrine as compared with hexobarbital].
    Zilly W; Wernze H; Buchenau D; Breimer DD; Richter E
    Verh Dtsch Ges Inn Med; 1975; 81():1677-80. PubMed ID: 1227056
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antipyrine excretion and aminopyrine breath test: use and significance in the assessment of liver function].
    Gugler R
    Z Gastroenterol; 1987 Mar; 25 Suppl 2():51-6. PubMed ID: 3590907
    [No Abstract]   [Full Text] [Related]  

  • 13. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of drug metabolism in polycystic non-parasitic liver disease.
    Sotaniemi EA; Luoma PV; Järvensivu PM; Sotaniemi KA
    Br J Clin Pharmacol; 1979 Oct; 8(4):331-5. PubMed ID: 508507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of effect of zinc supplementation on antipyrine clearance in alcoholic liver disease.
    Grønbaek K; Friis H; Feldman M; Sonne J; Andreasen PB
    Eur J Clin Pharmacol; 1996; 49(5):397-9. PubMed ID: 8866636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
    Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
    Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine clearance in pneumonia.
    Sonne J; Døssing M; Loft S; Andreasen PB
    Clin Pharmacol Ther; 1985 Jun; 37(6):701-4. PubMed ID: 4006370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between biochemical tests, parameters of drug elimination and hepatic enzyme induction in chronic liver diseases.
    Horváth T; Pár A; Beró T; Kádas I; Fábián C; Jávor T
    Acta Med Hung; 1983; 40(4):203-13. PubMed ID: 6674914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of albumin and alpha-1 acid glycoprotein on elimination of prazosin and antipyrine in the isolated perfused rat liver.
    Oie S; Fiori F
    J Pharmacol Exp Ther; 1985 Sep; 234(3):636-40. PubMed ID: 4032284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.